<DOC>
	<DOCNO>NCT00959218</DOCNO>
	<brief_summary>The purpose study determine whether Dronabinol effective safe relieve central neuropathic pain multiple sclerosis patient .</brief_summary>
	<brief_title>Efficacy Safety Pain Relieving Effect Dronabinol Central Neuropathic Pain Related Multiple Sclerosis</brief_title>
	<detailed_description>Multiple sclerosis ( MS ) probability autoimmune disease cause severe neurological disability due inflammation degeneration central nervous system ( CNS ) . MS affect 1 million people worldwide . Central neuropathic pain associate approximately 30 % patient MS. MS-accompanying pain major impact patient ' quality life usual conventional analgesic little effective . The aim clinical study determine whether Dronabinol effective safe relieve central neuropathic pain multiple sclerosis patient .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Diagnosis multiple sclerosis acc . McDonald diagnostic criterion EDSS score 3 8 ( incl . ) Patients stable phase multiple sclerosis Patients MSrelated central neuropathic pain least 3 month Severe concomitant diseases Certain concomitant therapy ( particular : pain influence concomitant therapy ) Dronabinol intake within last 12 month prior study entry Marihuana use within one month prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Dronabinol</keyword>
	<keyword>( - ) trans-delta9-tetrahydrocannabinol</keyword>
	<keyword>central neuropathic pain</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>analgesic</keyword>
	<keyword>Central neuropathic pain related multiple sclerosis</keyword>
</DOC>